$0.85
7.04% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US19249H1032
Symbol
CHRS
Sector
Industry

Coherus BioSciences, Inc. Target price 2025 - Analyst rating & recommendation

Coherus BioSciences, Inc. Classifications & Recommendation:

Buy
80%
Hold
20%

Coherus BioSciences, Inc. Price Target

Target Price $4.83
Price $0.91
Potential
Number of Estimates 3
3 Analysts have issued a price target Coherus BioSciences, Inc. 2026 . The average Coherus BioSciences, Inc. target price is $4.83. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 4 Analysts recommend Coherus BioSciences, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Coherus BioSciences, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Coherus BioSciences, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 266.96 101.72
3.78% 61.90%
EBITDA Margin -37.32% -188.55%
49.32% 405.27%
Net Margin 10.83% 5.36%
109.52% 50.49%

5 Analysts have issued a sales forecast Coherus BioSciences, Inc. 2025 . The average Coherus BioSciences, Inc. sales estimate is

$102m
Unlock
. This is
61.90% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$109m 59.16%
Unlock
, the lowest is
$95.0m 64.41%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $267m 3.78%
2025
$102m 61.90%
Unlock
2026
$111m 8.96%
Unlock
2027
$146m 31.41%
Unlock
2028
$152m 4.53%
Unlock
2029
$217m 42.61%
Unlock

2 Analysts have issued an Coherus BioSciences, Inc. EBITDA forecast 2025. The average Coherus BioSciences, Inc. EBITDA estimate is

$-192m
Unlock
. This is
106.42% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-133m 43.13%
Unlock
, the lowest is
$-251m 169.70%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-99.6m 47.41%
2025
$-192m 92.53%
Unlock
2026
$-163m 15.01%
Unlock
2027
$-11.5m 92.95%
Unlock
2028
$-76.0m 560.81%
Unlock
2029
$-54.0m 28.95%
Unlock

EBITDA Margin

2024 -37.32% 49.32%
2025
-188.55% 405.27%
Unlock
2026
-147.08% 21.99%
Unlock
2027
-7.90% 94.63%
Unlock
2028
-49.91% 531.77%
Unlock
2029
-24.87% 50.17%
Unlock

4 Coherus BioSciences, Inc. Analysts have issued a net profit forecast 2025. The average Coherus BioSciences, Inc. net profit estimate is

$5.5m
Unlock
. This is
72.27% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$298m 1,417.63%
Unlock
, the lowest is
$-239m 1,318.50%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $28.9m 109.88%
2025
$5.5m 81.14%
Unlock
2026
$-115m 2,213.94%
Unlock
2027
$-80.4m 30.18%
Unlock
2028
$-132m 63.85%
Unlock
2029
$-76.9m 41.67%
Unlock

Net Margin

2024 10.83% 109.52%
2025
5.36% 50.49%
Unlock
2026
-103.94% 2,039.18%
Unlock
2027
-55.22% 46.87%
Unlock
2028
-86.56% 56.75%
Unlock
2029
-35.41% 59.09%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 0.25 0.05
109.88% 80.00%
P/E 19.31
EV/Sales 2.73

4 Analysts have issued a Coherus BioSciences, Inc. forecast for earnings per share. The average Coherus BioSciences, Inc. EPS is

$0.05
Unlock
. This is
70.59% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$2.58 1,417.65%
Unlock
, the lowest is
$-2.07 1,317.65%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $0.25 109.88%
2025
$0.05 80.00%
Unlock
2026
$-1.00 2,100.00%
Unlock
2027
$-0.70 30.00%
Unlock
2028
$-1.14 62.86%
Unlock
2029
$-0.67 41.23%
Unlock

P/E ratio

Current 5.22 661.29%
2025
19.31 269.92%
Unlock
2026
-0.91 104.71%
Unlock
2027
-1.31 43.96%
Unlock
2028
-0.80 38.93%
Unlock
2029
-1.37 71.25%
Unlock

Based on analysts' sales estimates for 2025, the Coherus BioSciences, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.04 57.55%
2025
2.73 162.93%
Unlock
2026
2.51 8.22%
Unlock
2027
1.91 23.90%
Unlock
2028
1.83 4.34%
Unlock
2029
1.28 29.88%
Unlock

P/S ratio

Current 0.40 61.81%
2025
1.04 162.42%
Unlock
2026
0.95 8.22%
Unlock
2027
0.72 23.90%
Unlock
2028
0.69 4.34%
Unlock
2029
0.49 29.87%
Unlock

Current Coherus BioSciences, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 11 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 23 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 22 2025
Baird
Locked
Locked
Locked Dec 05 2024
HC Wainwright & Co.
Locked
Locked
Locked Dec 04 2024
Baird
Locked
Locked
Locked Nov 08 2024
HC Wainwright & Co.
Locked
Locked
Locked Nov 07 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 11 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 23 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 22 2025
Locked
Baird:
Locked
Locked
Dec 05 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 04 2024
Locked
Baird:
Locked
Locked
Nov 08 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 07 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today